Ibrutinib-MPEA

Overview

Ibrutinib -MPEA is an orally active, blood-brain barrier permeable inhibitor of BTK and STAT5 . As a derivative of Ibrutinib ( HY-10997 ) conjugated with a PROTAC linker , Ibrutinib -MPEA allows the synthesis of a series of PROTAC molecules. Ibrutinib -MPEA significantly reduces the proliferation of neoplastic mast cells and primary mastocytoma cells by inducing apoptosis and inhibiting IgE -dependent histamine release. Ibrutinib -MPEA is applicable to the research of canine mast cell tumors, cerebral ischemia/reperfusion injury in diabetic mice, and neuroinflammation-related diseases.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Autoimmune Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > PROTAC | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > JAK/STAT Signaling | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Signaling Pathways > Target Protein Ligand-Linker Conjugates | Products > Signaling Pathways > Btk | Products > Signaling Pathways > STAT

Product Information

• Catalog No.: HY-43521
• CAS No.: 1710768-30-1
• Molecular Formula: C32H39N9O2
• Molecular Weight: 581.71
• Purity: 99.71%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 3.33 mg/mL (5.72 mM); Clear solution
• Availability: In-stock

Source

Original product source